Submodule
Goals, Response, and Monitoring
The treatment target has three dimensions: the risk-based absolute goal, the percentage reduction from baseline, and evidence that the intended regimen was actually delivered.
- Untreated phenotype
- LDL-C and non-HDL-C goals
- Percentage response
- Follow-up and residual particle burden
Define phenotype and starting exposure
Choose the correct pathway
Use both dimensions
Explain every unexpected result
Reconstruct the starting phenotype
Use the best untreated LDL-C, non-HDL-C, triglyceride, apoB when useful, family history, age, and secondary-cause evaluation. If treatment was already started, prior records and response patterns can estimate baseline burden. One current value cannot reveal both severity and efficacy.
Use absolute goals and percentage response
The 2026 guideline restores LDL-C and non-HDL-C goals while retaining percentage LDL-C reduction. Borderline and intermediate primary prevention generally use LDL-C below 100 mg/dL and non-HDL-C below 130 mg/dL when therapy is selected. High primary risk uses below 70 and below 100. Very-high-risk secondary prevention uses below 55 and below 85.
Interpret the response, not only the result
An on-treatment value reflects baseline biology, dose, adherence, interactions, secondary causes, analytic method, and time since the change. A patient can have a strong percentage response and remain above goal, or reach an absolute goal with a smaller response because the baseline was modest.
Measure at an interpretable time
Repeat after sufficient time for the selected therapy to approach its expected effect and sooner when safety or severe disease requires it. Stable follow-up should still confirm persistence, access, adverse effects, and lifestyle or physiologic changes. ApoB can clarify residual burden after standard goals are met in selected discordant states.
Quick check
Submodule
Primary-Prevention Selection
Primary prevention calculates contemporary risk, personalizes beyond the equation, and uses CAC selectively when the medication decision is still uncertain.
- PREVENT 10- and 30-year risk
- Borderline, intermediate, and high categories
- Risk enhancers
- CAC reclassification
Use verified inputs in adults without disease
Add risk outside the equation
Resolve remaining uncertainty
Match intensity and goals to risk
Calculate with PREVENT
For eligible adults without known ASCVD or subclinical disease and with LDL-C in the calculator-supported range, PREVENT-ASCVD supplies contemporary 10-year and, when applicable, 30-year risk. Verify every input. Borderline is 3 to below 5 percent, intermediate is 5 to below 10 percent, and high begins at 10 percent.
Personalize the estimate
Premature family history, inflammatory disease, reproductive history, Lp(a), selected apoB use, triglycerides, CKD, HIV, and other enhancers can add risk information outside the equation. Do not count the same factor twice, and do not use an enhancer as a substitute for correcting the calculator inputs.
Reclassify only when uncertain
CAC can resolve selected borderline or intermediate decisions when each possible result has a planned consequence. A CAC score of at least 100 supports statin therapy, and extensive burden can justify secondary-prevention-like goals. CAC zero does not de-risk FH, diabetes in every circumstance, smoking, strong premature family history, or symptomatic disease.
Start at a plausible intensity
Borderline risk permits consideration after discussion, intermediate risk supports stronger consideration, and high risk calls for treatment toward LDL-C below 70 and non-HDL-C below 100. Choose a regimen capable of reaching the goal, then verify response and preference rather than defaulting to a token dose.
Quick check
Submodule
Secondary Prevention and Combination Therapy
Established ASCVD demands recurrent-event prevention, rapid goal attainment, and combination therapy selected by the reduction still required rather than by ritual sequencing.
- Very-high-risk classification
- LDL-C and non-HDL-C secondary goals
- Maximally tolerated statin
- Nonstatin combination and inertia
Set LDL-C and non-HDL-C goals
Do not delay foundational therapy
Estimate the reduction still needed
Escalate without therapeutic inertia
Begin with observed disease
Clinical ASCVD bypasses primary-prevention calculation. Determine whether the patient has multiple major events or one event plus high-risk conditions, then set the secondary-prevention goal. Most patients with prior ASCVD events will qualify for the very-high-risk pathway.
Use the correct secondary goal
Very-high-risk ASCVD uses LDL-C below 55 mg/dL and non-HDL-C below 85 mg/dL. ASCVD not at very high risk generally uses at least below 70 and below 100, while a lower goal can be reasonable by clinical judgment and preference. Percentage lowering remains important alongside the goal.
Combine according to the gap
A maximally tolerated statin remains foundational. Ezetimibe, PCSK9 monoclonal antibodies, bempedoic acid, and inclisiran differ in lowering magnitude, cardiovascular outcomes evidence, route, schedule, interactions, and access. When a large gap remains, planned combination therapy can be more rational than slow serial monotherapy.
Design against therapeutic inertia
Define who owns the repeat result, when it will be checked, what counts as inadequate response, and which therapy comes next. Verify fill history, administration, adverse effects, and affordability. An above-goal value without an explanation and action is a preventable systems failure.
Quick check
Submodule
Hypertriglyceridemia and Pancreatitis Prevention
Persistent triglycerides require cause correction and ASCVD prevention, while levels at or above 500 mg/dL increasingly add a pancreatitis-prevention objective and at least 1000 mg/dL suggest chylomicronemia.
- Secondary drivers
- ASCVD versus pancreatitis goals
- Severe hypertriglyceridemia
- FCS and multifactorial chylomicronemia
Glycemia, alcohol, diet, medicines, and disease
Treat apoB particle risk
Confirm fasting phenotype and consider TG therapy
Very-low-fat plan and specialist pathway
Correct what is driving production or clearance
Uncontrolled diabetes, alcohol, added sugars, excess energy, pregnancy, kidney or thyroid disease, weight change, and medications can markedly raise triglycerides. Correction can lower risk faster than adding a drug while the driver continues. Assess abdominal pain or vomiting urgently when pancreatitis is possible.
Keep statins foundational for ASCVD
For persistent triglycerides below 1000 mg/dL, statins remain the foundation of pharmacologic ASCVD risk reduction when indicated. Fibrates reduce triglycerides but have not shown routine incremental ASCVD benefit when simply added to statin therapy. Prescription icosapent ethyl has a separate product-specific cardiovascular pathway.
Add pancreatitis prevention at severe levels
At triglycerides of at least 500 mg/dL, confirm a persistent fasting phenotype, intensify cause correction, and consider fenofibrate or prescription omega-3 therapy for pancreatitis prevention. Gemfibrozil is not preferred with a statin because of its interaction and myopathy risk.
Treat chylomicronemia at at least 1000
At least 1000 mg/dL substantially increases pancreatitis risk and often indicates chylomicronemia. Use a very-low-fat plan, eliminate alcohol and added sugars, involve a dietitian and lipid specialist, and distinguish FCS from multifactorial disease. Current FCS care can include olezarsen in adults alongside diet.
Quick check
Submodule
Familial Disease and Lipoprotein(a)
Inherited dyslipidemia converts a current laboratory value into a lifetime and family problem. Treatment begins early and escalates according to residual receptor function and phenotype.
- Heterozygous FH
- Homozygous FH
- Cascade screening
- Elevated Lp(a)
Do not let a low short-term score de-risk FH
Reduce particle-years
Match pathway to HeFH or HoFH
Turn one diagnosis into prevention
Reduce particle-years in HeFH
HeFH produces high lifetime LDL exposure and premature ASCVD risk that general calculators underestimate. Use intensive statin-based therapy, add nonstatins to reach the risk-based goal, and screen relatives. Genetic testing can strengthen diagnosis and cascade detection, but a negative panel does not erase a clinical phenotype.
Recognize receptor failure in HoFH
HoFH can cause extreme LDL-C from birth, xanthomas, childhood coronary disease, and aortic root or valve disease. Statins, ezetimibe, bempedoic acid, and PCSK9-directed therapies may be blunted when LDL receptor activity is severely impaired. Evinacumab, lomitapide, and apheresis provide receptor-independent or bypass strategies.
Turn one diagnosis into family prevention
Cascade lipid testing is useful even when genetic testing is unavailable or nondiagnostic. Record which relative had which vascular event and at what age. Early detection in children and young adults changes cumulative exposure before symptoms appear.
Respond to elevated Lp(a) now
Lp(a) is measured at least once in adulthood and is largely inherited. Elevated values support more intensive LDL lowering and control of blood pressure, smoking, diabetes, and other modifiable risk. Do not use a universal mass-to-molar conversion or promise that standard LDL therapy specifically normalizes Lp(a).
Quick check
Submodule
Special Populations, Tolerance, and Access
A complete plan accounts for disease-specific recommendations, organ function, interacting therapy, reproductive context, symptom attribution, acquisition, and the patient's ability to sustain treatment.
- Diabetes, CKD, and HIV
- Pregnancy, youth, and older adults
- Statin-attributed muscle symptoms
- Adherence, access, and shared decisions
A prescription is not exposure
Confirm the actual regimen
Use an interpretable follow-up interval
Preserve risk reduction while solving barriers
Use special-population pathways
Adults 40 to 75 with diabetes, stage 3 or 4 CKD, or HIV generally receive primary-prevention LDL-lowering therapy regardless of LDL-C or PREVENT score. Kidney function, albuminuria, diabetes complications, and antiretroviral interactions determine the exact regimen. After 75, benefit, frailty, interactions, lifespan, and goals shape initiation or continuation.
Use a reproductive and lifecourse plan
Pregnancy and lactation require current product-specific guidance, preconception planning, and specialist care for severe inherited disease. Children with FH can require treatment beginning in childhood. Do not use retired pregnancy letters or wait for adult short-term risk to address severe childhood exposure.
Investigate statin-attributed muscle symptoms
A statin pattern is more likely with new bilateral proximal pain or weakness after initiation or dose increase, improvement after withdrawal, and recurrence with rechallenge. Review CK when indicated, thyroid, kidney, exercise, interacting drugs, and other causes. Use the maximally tolerated daily or less-than-daily statin plus evidence-based nonstatins.
Confirm exposure and solve access
A prescription is not exposure. Verify fills, dose and schedule, injection dates, storage, technique, adverse effects, cost, prior authorization, pharmacy delivery, health literacy, and preference. Simplify where possible and assign follow-up ownership before adding complexity.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- ACC and AHA. 2026 Dyslipidemia Guideline
- American College of Cardiology. Lower Sooner and 2026 Dyslipidemia Practice
- American College of Cardiology. 2026 Dyslipidemia Guideline Summary
- American Heart Association. Statin Safety Scientific Statement
- American Heart Association. Lipoprotein(a) Scientific Statement